PMID- 37519536
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 15
IP  - 6
DP  - 2023 Jun
TI  - Angiotensin II Type 1 Receptor Antibody-Mediated Kidney Rejection Unresponsive to 
      Treatment.
PG  - e41007
LID - 10.7759/cureus.41007 [doi]
LID - e41007
AB  - Allograft rejection is a significant cause of renal transplant failure which 
      needs prompt diagnosis and treatment for graft salvage. Angiotensin II type 1 
      receptor antibody-mediated rejection (AT1R-AMR) is increasingly being identified 
      as the etiology of antibody-mediated rejection in kidney transplant recipients 
      with allograft rejection but without detectable human leukocyte antigen (HLA) 
      antibodies. While some reports have suggested that AT1R-AMR may be refractory to 
      standard therapy, others have reported improvement or stabilization of graft 
      function. We present two patients in which anti-rejection therapy including 
      therapeutic plasma exchange was unable to salvage the allograft.
CI  - Copyright (c) 2023, Allison et al.
FAU - Allison, David
AU  - Allison D
AD  - Pathology, University of Illinois at Chicago, Chicago, USA.
FAU - Hajjiri, Zahraa
AU  - Hajjiri Z
AD  - Transplant Nephrology, University of Illinois at Chicago, Chicago, USA.
FAU - Manon, Luis
AU  - Manon L
AD  - Pathology, University of Illinois at Chicago, Chicago, USA.
FAU - Campbell-Lee, Sally
AU  - Campbell-Lee S
AD  - Pathology, University of Illinois at Chicago, Chicago, USA.
FAU - Sahni, Suhalika
AU  - Sahni S
AD  - Pathology, University of Illinois at Chicago, Chicago, USA.
FAU - Setty, Suman
AU  - Setty S
AD  - Pathology, University of Illinois at Chicago, Chicago, USA.
LA  - eng
PT  - Case Reports
DEP - 20230626
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC10371875
OTO - NOTNLM
OT  - apheresis therapy
OT  - at1r antibody
OT  - kidney allograft
OT  - non-hla antibody
OT  - renal transplant rejection
OT  - therapeutic plasma exchange (tpe)
COIS- The authors have declared that no competing interests exist.
EDAT- 2023/07/31 06:42
MHDA- 2023/07/31 06:43
PMCR- 2023/06/26
CRDT- 2023/07/31 04:38
PHST- 2023/06/25 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/07/31 06:42 [pubmed]
PHST- 2023/07/31 04:38 [entrez]
PHST- 2023/06/26 00:00 [pmc-release]
AID - 10.7759/cureus.41007 [doi]
PST - epublish
SO  - Cureus. 2023 Jun 26;15(6):e41007. doi: 10.7759/cureus.41007. eCollection 2023 
      Jun.